Marijuana rescheduling was supposed to give U.S. cannabis companies some much-needed relief. Instead, another regulatory dispute threatens to drag out a process that's already taken years. The latest snag involves a Government Accountability Office report on how federal agencies evaluate controlled substances, and the fight over what belongs in the administrative record.
A procedural fight with real financial stakes
Opponents of rescheduling want the GAO report entered into the record, along with additional testimony and document access. The DEA says it doesn't object to including the report itself. That sounds like a minor concession, but the broader requests for testimony and documents are the part that could stretch the timeline. Administrative proceedings like this one run on process, not urgency, and every new filing or evidentiary request gives either side grounds to request more time. For multi-state operators who've been budgeting around an eventual move from Schedule I to Schedule III, that's a familiar kind of frustration: the finish line keeps shifting.
The reason this matters so much comes down to Section 280E of the federal tax code. Because cannabis remains a Schedule I substance, plant-touching businesses generally can't deduct ordinary operating expenses - payroll, rent, advertising - when calculating federal taxable income. It's a tax structure no other legal industry operates under. Moving to Schedule III would lift that restriction for qualifying activity, potentially freeing up meaningful cash for reinvestment in retail buildout, compliance infrastructure, or debt reduction. Until a final rule is issued and implemented, though, operators have to keep running the business as if none of that is coming.
Green Thumb's numbers already tell a story
Green Thumb Industries (OTC: GTBIF) offers a useful case study precisely because its results don't depend on Washington getting anything done. In the second quarter of 2026, the company generated $29 million in operating cash flow on revenue of $306.7 million, with normalized EBITDA of $84.3 million and net income of $4.9 million. Those are the results of a company absorbing the full weight of 280E and still posting positive earnings. That's worth sitting with. A lot of multi-state operators talk about reaching profitability as a future milestone; Green Thumb is already producing cash under the harshest version of the current rules.
At roughly $6.40 per share, the company carries a market capitalization near $1.4 billion - about 1.1 times annualized second-quarter revenue. For an operator with an established dispensary footprint, positive earnings, and real cash generation, that's not an expensive multiple. It also means the stock isn't priced as if rescheduling is baked in. If the tax relief eventually arrives, it's upside on top of a business that already works. If it doesn't arrive on schedule - and recent developments suggest it won't arrive quickly - the underlying retail and wholesale operations still have to carry the story.
What this means for operators watching from the sidelines
The practical lesson for other licensed operators isn't about stock picking. It's about planning horizons. Dispensary owners and brand operators building five-year plans around a 280E repeal should treat that relief as a bonus scenario, not a baseline assumption. Compliance teams, finance departments, and wholesale pricing strategies all need to function under current tax law until a rule is finalized, published, and survives whatever challenges follow. Rescheduling would still leave marijuana federally controlled, meaning interstate commerce restrictions, banking caution, and state-level licensing and seed-to-sale tracking requirements wouldn't simply disappear. The tax fix is significant, but it's one piece of a much larger compliance picture that dispensary operators have to manage every day regardless of what happens in the administrative record.
